Evidence map›Paper›PMID 40253324›Full record

ArticleBMC nephrology2025

Renalase, dopamine, and norepinephrine as markers for the development of hypertension in CKD patients.

Rafał Heryć, Elżbieta Cecerska-Heryć, Natalia Serwin, Patrycja Stodolak, Małgorzata Goszka, Aleksandra Polikowska, Kazimierz Ciechanowski, Magda Wiśniewska

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Rafał HeryćDepartment of Nephrology, Transplantology and Internal Medicine, Pomeranian Medical University of Szczecin, Powstancow Wielkopolskich 72, Szczecin, 70-111, Poland.
Elżbieta Cecerska-HeryćDepartment of Laboratory Medicine, Pomeranian Medical University of Szczecin, Powstanców Wielkopolskich 72, Szczecin, 70-111, Poland. elzbieta.cecerska.heryc@pum.edu.pl.
Natalia SerwinDepartment of Laboratory Medicine, Pomeranian Medical University of Szczecin, Powstanców Wielkopolskich 72, Szczecin, 70-111, Poland.
Patrycja StodolakDepartment of Laboratory Medicine, Pomeranian Medical University of Szczecin, Powstanców Wielkopolskich 72, Szczecin, 70-111, Poland.
Małgorzata GoszkaDepartment of Laboratory Medicine, Pomeranian Medical University of Szczecin, Powstanców Wielkopolskich 72, Szczecin, 70-111, Poland.
Aleksandra PolikowskaDepartment of Laboratory Medicine, Pomeranian Medical University of Szczecin, Powstanców Wielkopolskich 72, Szczecin, 70-111, Poland.
Kazimierz CiechanowskiDepartment of Nephrology, Transplantology and Internal Medicine, Pomeranian Medical University of Szczecin, Powstancow Wielkopolskich 72, Szczecin, 70-111, Poland.
Magda WiśniewskaDepartment of Nephrology, Transplantology and Internal Medicine, Pomeranian Medical University of Szczecin, Powstancow Wielkopolskich 72, Szczecin, 70-111, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionChronic kidney disease (CKD) leads to irreversible changes in kidney function and structure, with over 90% of patients developing arterial hypertension (HT). Renalase, dopamine, and norepinephrine are believed to influence HT development and CKD progression. AIM OF THE STUDY: This study aims to measure renalase, dopamine, and norepinephrine levels in CKD patients to evaluate their potential as markers for CKD progression, HT development, and cardiovascular event risk. MATERIALS AND

methodsThe study involved 117 CKD patients divided into four groups: 32 hemodialysis patients (before and after treatment), 31 peritoneal dialysis patients, 24 kidney transplant recipients (pre- and post-transplant), and 30 conservatively treated patients (CKD stages 2-5). A control group included 31 healthy volunteers. Levels of renalase, dopamine, and norepinephrine were measured using the ELISA method.

resultsThe study found that CKD significantly affected renalase, dopamine, and norepinephrine levels (p = 0.046; p = 0.035; p = 0.023). The lowest renalase levels were in patients with ADPKD and HT, while the highest dopamine levels were in those with CKD due to glomerulonephritis. The lowest norepinephrine levels were observed in patients with HT and diabetes.

conclusionsLevels of renalase, dopamine, and norepinephrine may indicate CKD progression, cardiovascular event risk, and patient prognosis.

Indexed as

DopamineHypertensionMonoamine OxidaseNorepinephrineRenal Insufficiency, ChronicAdultAgedBiomarkersDisease ProgressionFemaleHumansKidney TransplantationMaleMiddle AgedBiomarkersDopamineMonoamine OxidaseNorepinephrinerenalaseChronic kidney diseaseDopamineHypertensionNorepinephrineRenalase

Identifiers

PMID40253324
PMCPMC12009526

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.